Article

Are You Prepared To Move A Bioconjugate Candidate From Clinic To Market?

iStock-1213498599-microscope-cannabis-scientist-research

Antibody drug conjugates (ADCs) have become a groundbreaking tool in the industry’s fight against cancer, offering new opportunities for innovation and progress in patient care. These highly targeted biopharmaceutical drugs are one of the fastest growing anticancer drugs, with nine of the ten ADCs currently on the market approved just in the last decade and more than 80 ADCs in today’s pipeline.1 Beside ADCs, bioconjugates with non-cytotoxic modifications are emerging and are on the verge of market authorization. Nevertheless, despite the potential of ADCs and other bioconjugates, they present a wide range of challenges for drug manufacturers trying to navigate their way to commercial success.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: